SEC Form 4 · accession 0002020969-26-000004
RECURSION PHARMACEUTICALS, INC. · RXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Najat Khan
Officer — CEO and President · Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 5, 2026 · 5:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001601830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Jun 5, 2026 | S | 23,588 | $3.5806 | D | 2,175,796 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $3.56 to $3.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.